D. Goodman

发表

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

T. Kepler, B. Korber, H. Liao, 2017, Nature Communications.

Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV

D. Lauffenburger, B. Haynes, J. Weiner, 2018, Nature Medicine.

Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial

Lindsay N. Carpp, Allan C. deCamp, S. Hammer, 2019, Journal of Virology.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120

Lindsay N. Carpp, Allan C. deCamp, Jerome H. Kim, 2017, PloS one.

Reduced Viral Fitness and Lack of Cross-Class Resistance with Integrase Strand Transfer Inhibitor and Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations

K. White, D. Goodman, M. Miller, 2015, Antimicrobial Agents and Chemotherapy.

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study

K. White, K. Borroto-Esoda, E. Svarovskaia, 2009, Retrovirology.

Low-Level K65R Mutation in HIV-1 Reverse Transcriptase of Treatment-Experienced Patients Exposed to Abacavir or Didanosine

K. Borroto-Esoda, Lijie Zhong, E. Svarovskaia, 2007, Journal of acquired immune deficiency syndromes.

Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models

T. Hope, D. Montefiori, G. Ferrari, 2019, Journal of Virology.

The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R Mutation

K. White, K. Borroto-Esoda, E. Svarovskaia, 2008, Journal of acquired immune deficiency syndromes.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

J. Mascola, D. Montefiori, R. Bailer, 2017, PLoS medicine.

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

K. White, Xiaowu Chen, E. Svarovskaia, 2013, Antimicrobial Agents and Chemotherapy.

Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates

B. Korber, H. Liao, Laura L. Sutherland, 2018, Journal of Virology.

Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers

Rachel L. Spreng, Sarah V. Mudrak, T. Hope, 2021, Frontiers in Immunology.

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

K. Borroto-Esoda, Lijie Zhong, E. Svarovskaia, 2011, AIDS.

A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago.

W. Blattner, T. O'Brien, J. Carr, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

D. Weissman, Laura L. Sutherland, B. Haynes, 2021, NPJ vaccines.

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.

Allan C. deCamp, S. Hammer, J. Mascola, 2019, The Journal of clinical investigation.

Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques

Rachel L. Spreng, T. Hope, M. Tay, 2021, Frontiers in Immunology.

Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s

Sarah V. Mudrak, G. Ferrari, M. A. Moody, 2022, Frontiers in Immunology.

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

D. Weissman, Laura L. Sutherland, B. Haynes, 2021, npj Vaccines.

Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV

D. Lauffenburger, B. Haynes, J. Weiner, 2018, Nature Medicine.

Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response

Rachel L. Spreng, Lindsay C. Dahora, Jerome H. Kim, 2023, PLoS pathogens.

Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

D. Weissman, Laura L. Sutherland, B. Haynes, 2020, npj Vaccines.

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions

B. Haynes, R. Baric, G. Ferrari, 2023, bioRxiv.

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

K. Borroto-Esoda, Lijie Zhong, E. Svarovskaia, 2011, AIDS.

Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates

B. Korber, Laura L. Sutherland, B. Haynes, 2018, Journal of Virology.

Multivariate analysis of FcR-mediated NK cell functions identifies unique clustering among humans and rhesus macaques

Rachel L. Spreng, T. Gurley, M. A. Moody, 2023, Frontiers in immunology.